<code id='FD1B03C812'></code><style id='FD1B03C812'></style>
    • <acronym id='FD1B03C812'></acronym>
      <center id='FD1B03C812'><center id='FD1B03C812'><tfoot id='FD1B03C812'></tfoot></center><abbr id='FD1B03C812'><dir id='FD1B03C812'><tfoot id='FD1B03C812'></tfoot><noframes id='FD1B03C812'>

    • <optgroup id='FD1B03C812'><strike id='FD1B03C812'><sup id='FD1B03C812'></sup></strike><code id='FD1B03C812'></code></optgroup>
        1. <b id='FD1B03C812'><label id='FD1B03C812'><select id='FD1B03C812'><dt id='FD1B03C812'><span id='FD1B03C812'></span></dt></select></label></b><u id='FD1B03C812'></u>
          <i id='FD1B03C812'><strike id='FD1B03C812'><tt id='FD1B03C812'><pre id='FD1B03C812'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:9577
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more
          Innovation in antibiotics is ailing. 'Brain drain' may kill it
          Innovation in antibiotics is ailing. 'Brain drain' may kill it

          Asantibioticsresearchshrivels,thebraindrainawayfromthisfieldwillhavemanylabslookingthisempty.AdobeIn

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          At ASCO, AstraZeneca reports strong data for breast cancer drug

          ThefuturelooksevenbrighterfortheblockbusterEnhertu,showcasedhereatASCO.ADAMFEUERSTEIN/STATCHICAGO—Th